Photodynamic therapy (
PDT) involves the activation of a photosensitizing
drug, which preferentially localizes to diseased skin, by irradiation with light to cause selective cytotoxic damage. Since its discovery in the early 20th century and the development of topical
photosensitizers 2 decades ago,
PDT is increasingly being used in dermatology for a wide range of neoplastic, inflammatory, and infectious cutaneous conditions. Topical 5-aminolevulinic
acid and methyl
aminolevulinic acid, the most commonly used agents in
PDT, have received Food and Drug Administration approval for the treatment of
actinic keratoses, and many second-generation
photosensitizers are under investigation. Compared with conventional
therapies,
PDT has the advantage of being noninvasive and capable of field treatment. It is also associated with quicker recovery periods and excellent cosmetic results. Because of these benefits,
PDT is being evaluated as a potential treatment option for many dermatologic conditions and has been shown to be effective for certain nonmelanoma
skin cancers. Although research is still limited,
PDT might also have a therapeutic benefit for
cutaneous T-cell lymphoma,
acne,
psoriasis,
leishmaniasis, and
warts, among others. This article is a review of the clinical applications of
PDT in dermatology and summarizes the current evidence in literature describing its efficacy, safety, and cosmetic outcome.